GRAL - GRAIL, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$75.67
DETAILS
HIGH:
$130.00
LOW:
$56.00
MEDIAN:
$65.00
CONSENSUS:
$75.67
UPSIDE:
12.62%
About GRAIL, Inc. (https://grail.com)
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Robert Ragusa | Chief Executive Officer & Director | 1960 | $1,616,399 USD |
| Aaron Freidin | Chief Financial Officer | 1979 | $1,134,942 USD |
| Joshua J. Ofman | President & Director | 1965 | $1,123,985 USD |
| Abram Barth | General Counsel & Corporate Secretary | – | – |
| Alexis Tosti | Vice President of Strategy & Corporate Development | – | – |
| Alison Highlander | Senior Vice President of Human Resources & Head of People Team | – | – |
| Andrew John Partridge | Chief Commercial Officer | 1969 | – |
| Eric T. Fung | Senior Vice President of Clinical Development | 1970 | – |
| Linda J. Peters | Senior Vice President of Quality & Regulatory | 1978 | – |
| Paul Ciccolella | Senior Vice President of Global Development & Operations | – | – |
| Satnam Alag | Senior Vice President of Software Engineering & Chief Security Officer | – | – |
| Sir Harpal S. Kumar | Chief Scientific Officer & President International | – | – |